| |
| In fact, STALEVO extends the benefits of carbidopa/levodopa by providing an average of 1.4 more "on" time hours per day. STALEVO is the most recent advance in levodopa therapy. It contains:
|
| |
- Carbidopa, which inhibits the action of dopa decarboxylase, an enzyme in the body that breaks down levodopa, making more dopamine available to receptors in the brain
- Levodopa, which is converted by the body into dopamine to replace, or supplement, the dopamine no longer produced by the brain, is the most widely prescribed treatment for PD
- Entacapone, which is added to inhibit the action of catechol-O-methyltransferase
(COMT), another enzyme in the body that breaks down levodopa, to further inhibit the breakdown of levodopa in the body before it reaches the brain
|
| |
| Because STALEVO contains entacapone, it provides a more persistent presence of levodopa in the body, leading to more consistent symptom control than carbidopa/levodopa. |
| |
| |
STALEVO is clinically proven to improve functionality and has been shown to deliver more active time during the day—an average of almost an hour and a half each day (1.4 hours). So you can enjoy more time with fewer symptoms.
Talk to your health care professional (HCP) if you have questions about STALEVO.
If you are taking carbidopa/levodopa and COMTAN® (entacapone) 200 mg tablets, you might be able to switch to STALEVO, a single tablet that contains all 3 drugs: carbidopa, levodopa, and entacapone.
For patients with PD experiencing symptom reemergence due to levodopa "wearing-off", STALEVO can be used to replace carbidopa/levodopa.
|
|
|
